^
Association details:
| Biomarker: | GPX2 underexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Lenvima (lenvatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma
Published date:
03/21/2022
Excerpt:
...we analyzed the expression of GPX2 in 22 patients who received lenvatinib….To our interest, 44.4% (4/9) of HCC patients with low GPX2 were responders (CR+PR), while most patients (12/13) with high GPX2 were non-responders (SD+PD)...
DOI:
https://doi.org/10.1016/j.jare.2022.03.012